Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas O McDonald

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Bioinformatics (Oxford, England)|March 24, 2017
SIApopr: a computational method to simulate evolutionary branching trees for analysis of tumor clonal evolutionThomas O McDonald, Franziska Michor
Mathematical Biosciences|November 19, 2009
A stochastic model of cell cycle desynchronizationPeter Olofsson, Thomas O McDonald
Nature Genetics|October 31, 2018
Currently available bulk sequencing data do not necessarily support a model of neutral tumor evolutionThomas O McDonald, Shaon Chakrabarti, Franziska Michor
Bioinformatics (Oxford, England)|March 1, 2019
DIFFpop: a stochastic computational approach to simulate differentiation hierarchies with single cell barcodingJeremy Ferlic, Jiantao Shi, Thomas O McDonald, et al.
Bioinformatics (Oxford, England)|May 20, 2020
ESTIpop: a computational tool to simulate and estimate parameters for continuous-time Markov branching processesJames P Roney, Jeremy Ferlic, Franziska Michor, et al.
Cancer Research|June 21, 2020
Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug ResistanceItziar Irurzun-Arana, Thomas O McDonald, Iñaki F Trocóniz, et al.
Trends in Pharmacological Sciences|October 9, 2020
Beyond Deterministic Models in Drug Discovery and DevelopmentItziar Irurzun-Arana, Christopher Rackauckas, Thomas O McDonald, et al.
Journal for Immunotherapy of Cancer|June 19, 2025
Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao <i>et al</i>Christopher Graser, Thomas O McDonald, Paul J Catalano, et al.
Cancer Research|November 17, 2025
BESTDR Enables Bayesian Quantification of Mechanism-Specific Drug ResponsesThomas O McDonald, Simone Bruno, James P Roney, et al.
Journal for Immunotherapy of Cancer|May 9, 2025
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumabChristopher J Graser, Thomas O McDonald, Paul J Catalano, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Bioinformatics (Oxford, England)|March 24, 2017
SIApopr: a computational method to simulate evolutionary branching trees for analysis of tumor clonal evolutionThomas O McDonald, Franziska Michor
Mathematical Biosciences|November 19, 2009
A stochastic model of cell cycle desynchronizationPeter Olofsson, Thomas O McDonald
Nature Genetics|October 31, 2018
Currently available bulk sequencing data do not necessarily support a model of neutral tumor evolutionThomas O McDonald, Shaon Chakrabarti, Franziska Michor
Bioinformatics (Oxford, England)|March 1, 2019
DIFFpop: a stochastic computational approach to simulate differentiation hierarchies with single cell barcodingJeremy Ferlic, Jiantao Shi, Thomas O McDonald, et al.
Bioinformatics (Oxford, England)|May 20, 2020
ESTIpop: a computational tool to simulate and estimate parameters for continuous-time Markov branching processesJames P Roney, Jeremy Ferlic, Franziska Michor, et al.
Cancer Research|June 21, 2020
Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug ResistanceItziar Irurzun-Arana, Thomas O McDonald, Iñaki F Trocóniz, et al.
Trends in Pharmacological Sciences|October 9, 2020
Beyond Deterministic Models in Drug Discovery and DevelopmentItziar Irurzun-Arana, Christopher Rackauckas, Thomas O McDonald, et al.
Journal for Immunotherapy of Cancer|June 19, 2025
Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao <i>et al</i>Christopher Graser, Thomas O McDonald, Paul J Catalano, et al.
Cancer Research|November 17, 2025
BESTDR Enables Bayesian Quantification of Mechanism-Specific Drug ResponsesThomas O McDonald, Simone Bruno, James P Roney, et al.
Journal for Immunotherapy of Cancer|May 9, 2025
Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumabChristopher J Graser, Thomas O McDonald, Paul J Catalano, et al.
Pageof 5